Common Warts Market Report 2026

Common Warts Market Overview

• Common Warts market size has reached to $2.25 billion in 2025 • Expected to grow to $2.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Rising Viral Infections Driving Market Growth • Market Trend: Enhancing Treatment Efficacy Through Clinical Trials • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Common Warts Market?

Common warts are non-cancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, and other areas, serving as a defense mechanism for the body in response to the viral infection. The main treatment types of common warts are cryotherapy, laser treatment, electrosurgery, and topical medications. Cryotherapy is a treatment that uses extreme cold, typically liquid nitrogen, to freeze and destroy abnormal tissue. These treatments are administered across various patient demographics, including children, adults, and the elderly. The approach to treatment varies depending on the disease stage, with options tailored for the initial stage, moderate stage, and severe stage. The treatment is provided to different end users, such as hospitals, dermatology clinics, and home care.

What Is The Common Warts Market Growth Forecast?

The common warts market size is expected to see strong growth in the next few years. It will grow to $2.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand for non-invasive dermatological treatments, rising focus on cosmetic dermatology solutions, expansion of homecare dermatology products, growing adoption of laser-based therapies, increasing investment in immunomodulatory treatments. Major trends in the forecast period include advancements in minimally invasive wart removal techniques, rising adoption of combination therapy approaches, increased availability of over-the-counter treatments, growing use of immunotherapy-based topicals, expansion of home-based treatment options.

What Is The Driver Of The Common Warts Market?

The increasing incidence of viral infections is expected to propel the growth of the common warts market going forward. Viral infections refer to illnesses caused by viruses entering, multiplying, and spreading within the body, affecting cells and immune responses. The increasing incidence of viral infections is driven by globalization, climate change, urbanization, deforestation, and weakened immune responses. Common warts treatment targets the human papillomavirus (HPV) responsible for wart formation, and provides essential support for viral infection patients by reducing the spread of the virus, alleviating discomfort, and promoting healing, thus preventing complications such as secondary infections or scarring while improving the patient’s quality of life. For instance, in 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022 the proportion of PCR-confirmed varicella cases rose by 62%, increasing from 29% to 47% over the past five years. Furthermore, in January 2023, according to the National Foundation for Infectious Diseases, a US-based health organization, annually, there are an estimated 14 million new cases of HPV infection in the United States. Therefore, the increasing incidence of viral infections is driving growth in the common warts industry.

Key Players In The Global Common Warts Market

Major companies operating in the common warts market are GSK plc, Perrigo Company plc, Holland & Barrett International Limited, Prestige Consumer Healthcare Inc., Novan Inc., Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., Scholl’s Wellness Company, Naturasil, Bausch Health Companies Inc., Viatris Inc., Sanofi S.A., Pfizer Inc., Bayer AG, Novartis AG, Dr Reddy’s Laboratories Ltd, Cipla Inc, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, AIM ImmunoTech Inc, Phio Pharmaceuticals Corp, Euro Vital Pharma GmbH, Koninklijke Utermöhlen NV, Lumenis Be Ltd, Almirall S.A, Daiichi Sankyo Company Ltd

Global Common Warts Market Trends and Insights

Major companies operating in the common warts market are focusing on the advancing innovative treatments, such as dermatological therapies, to meet the growing demand for effective and accessible solutions, aiming to improve patient outcomes and expand their market presence in the dermatology sector. Dermatological therapies refer to treatments for skin conditions, including infections, inflammations, and disorders. For instance, in May 2024, Verrica Pharmaceuticals, a US-based pharmaceutical company, entered into a license agreement with Torii Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company. The collaboration aims to fund a global Phase 3 clinical trial for YCANTH, a treatment for common warts. This agreement supports the late-stage development of YCANTH, expanding its potential global reach. Torii Pharmaceuticals will contribute financial resources to advance the study. The collaboration strengthens both companies' dermatology portfolios and international market presence.

What Are Latest Mergers And Acquisitions In The Common Warts Market?

In June 2023, Vial, a US-based clinical trial management organization, collaborated with Nielsen BioSciences to conduct a Phase 3 clinical trial for CANDIN. This partnership aims to further the development of CANDIN as a potential treatment for common warts by assessing its safety and efficacy. Nielsen BioSciences is a US-based biotechnology company specializing in immune-based therapies, is contributing to this effort by advancing CANDIN as a promising treatment option.

What Defines the Common Warts Market?

The common warts market consists of revenues earned by entities by providing services such as telemedicine consultations, therapy services, and surgical excision. The market value includes the value of related goods sold by the service provider or included within the service offering. The common warts market also includes sales of over-the-counter (OTC) treatments, prescription medications, and medical devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Common Warts Market Report 2026?

The common warts market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the common warts industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.